Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Press Release

ORI Teams Up With World Class Investors to Close The Series C Financing in Kymab

ORI Healthcare Fund
Posted on: 29 Nov 16

HONG KONG, CHINA--(Marketwired - Nov 24, 2016) - ORI Healthcare Fund L.P. ("ORI Fund") announces that it has led a US$100 million Series-C investment in Kymab Group Limited (the "Company" or "Kymab"), a UK Cambridge-based company focusing on generating high-quality, fully humanized antibodies to treat challenging diseases based on the proprietary Kymouse™ antibody platform. ORI Fund is the lead investor in the series, other investors include Wellcome Trust, Bill & Melinda Gates Foundation, Shenzhen Hepalink Pharmaceutical Co., Ltd, Malin Corporation plc; CF Woodford Equity Income Fund and Woodford Patient Capital plc.

Kymab's Kymouse™ platform is widely regarded as the most exquisitely engineered antibody discovery platform developed to date. Kymouse™ contains the entire repertoire of human antibodies. The platform has the capability to discover antibodies that are difficult to develop and produce as it naturally matures these molecules to highly potent drugs obviating the need for further time-consuming modifications.

The Company currently has 12 pre-clinical programs under development that are with a strong focus on immuno-oncology while also covering hematology, autoimmune disease and infectious disease. The scientific and research efforts are led by teams of world-class scientists and industry veterans. The Company will continue to build a strong pipeline of antibody candidates.

The transaction is consistent with ORI Fund's investment philosophy to invest in innovative platform companies that can continuously innovate and produce important life-saving drugs. "We are very fortunate to have the opportunity to invest in Kymab which has a world class technology platform, world class pipeline, world class management team and world class investor base. We will contribute to the growth of Kymab by supporting Kymab's China strategies and execution leveraging our expertise and network in China", commented Ms. Simone Song, Senior Partner of ORI Fund.

About ORI Healthcare Fund

ORI Fund is a US$200 million venture capital fund focused on investing in innovative companies with disruptive technologies in the healthcare industry globally. The fund is founded by Ms. Simone (Hong Fang) Song, former investment banker and head of China Healthcare at Goldman Sachs. The team consists mostly of former Goldman Sachs bankers and healthcare scientists. The Fund is supported by a network of most renowned scientists, practitioners and entrepreneurs.

For more information:
www.marketwired.com/press-release/ori-teams-up-with-world-class-investors-to-close-the-series-c-financing-in-kymab-2178290.htm

Editor's Details

Mike Wood
PharmiWeb.com
www.pharmiweb.com
editor@pharmiweb.com

Last updated on: 29/11/2016

Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.